The Measles & Rubella Initiative is a global entity that provides funding and technical support directly to countries to address measles and rubella outbreaks. Through annual funding from Gavi, the Vaccine Alliance, and other supporters the M&RI partners are able to rapidly provide resources to countries experiencing outbreaks for targeted response activities including the purchase of vaccines and operational costs. M&RI has provided technical support to numerous countries working to prevent and stop measles outbreaks. This support is pivotal and sets M&RI and its five founding partners apart, making it all the more unique. In addition to technical support, M&RI Outbreak Response Funds have been provided to five countries (table.)
Countries Receiving M&RI Outbreak Response Funds in 2022
| Country | Target Population | Date Approved |
|---|---|---|
| Afghanistan | 1,229,926 | February 23, 2022 |
| DRC | 2,678,973 | March 24, 2022 |
| Liberia | 343,180 | May 11, 2022 |
| Yemen | 1,355,142 | May 20, 2022 |
| Niger | 992,259 | July 11, 2022 |
| Northwest Syria | 535,688 | July 12, 2022 |
| Ethiopia | 591,243 | August 15, 2022 |
| Cameroon | 1,112,576 | September 2, 2022 |
Measles News
Read the latest news about ongoing immunization campaigns throughout the world.
- COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades
- UNICEF and WHO warn of ‘perfect storm’ of conditions for measles outbreaks, affecting children
- From the Frontlines: Stopping Measles Outbreaks in Brazil
- Over 100,000 people sick with measles in 14 months
Interactive map
A dynamic visual aide showing current progress and challenges in the Measles & Rubella Initiative’s campaigns.
2021-2023 Measles Outbreaks Strategic Response Plan (MOSRP)
WHO together with its global and regional MR partners have identified a list of priority countries for enhanced outbreak preparedness and response support as part of the 2021-2023 Measles Outbreaks Strategic Response Plan (MOSRP). The list of priority countries is being regularly revised to account for changes on measles epidemiologic risk. You can find the latest version here.
Additional Links
Prelude Version 2.3.2